Literature DB >> 1400481

Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties.

Y Okada1, Y Gonoji, K Naka, K Tomita, I Nakanishi, K Iwata, K Yamashita, T Hayakawa.   

Abstract

Matrix metalloproteinase 9 (MMP-9) has been purified as an inactive zymogen of M(r) 92,000 (proMMP-9) from the culture medium of HT 1080 human fibrosarcoma cells. The NH2-terminal sequence of proMMP-9 is Ala-Pro-Arg-Gln-Arg-Gln-Ser-Thr-Leu-Val-Leu-Phe-Pro, which is identical to that of the 92-kDa type IV collagenase/gelatinase. The zymogen can be activated by 4-aminophenylmercuric acetate, yielding an intermediate form of M(r) 83,000 and an active species of M(r) 67,000, the second of which has a new NH2 terminus of Met-Arg-Thr-Pro-Arg-(Cys)-Gly-Val-Pro-Asp-Leu-Gly-Arg-Phe-Gln-Thr- Phe-Glu. Immunoblot analyses demonstrate that this activation process is achieved by sequential processing of both NH2- and COOH-terminal peptides. TIMP-1 complexed with proMMP-9 inhibits the conversion of the intermediate form to the active species of M(r) 67,000. The proenzyme is fully activated by cathepsin G, trypsin, alpha-chymotrypsin, and MMP-3 (stromelysin 1) but not by plasmin, leukocyte elastase, plasma kallikrein, thrombin, or MMP-1 (tissue collagenase). During the activation by MMP-3, proMMP-9 is converted to an active species of M(r) 64,000 that lacks both NH2- and COOH-terminal peptides. In addition, HOCl partially activates the zymogen by reacting with an intermediate species of M(r) 83,000. The enzyme degrades type I gelatin rapidly and also cleaves native collagens including alpha 2 chain of type I collagen, collagen types III, IV, and V at undenaturing temperatures. These results indicate that MMP-9 has different activation mechanisms and substrate specificity from those of MMP-2 (72-kDa gelatinase/type IV collagenase).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400481

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  88 in total

1.  MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits.

Authors:  A M Tester; N Ruangpanit; R L Anderson; E W Thompson
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue.

Authors:  Zhong Dong; R Daniel Bonfil; Sreenivasa Chinni; Xiyun Deng; J Carlos Trindade Filho; Margarida Bernardo; Ulka Vaishampayan; Mingxin Che; Bonnie F Sloane; Shijie Sheng; Rafael Fridman; Michael L Cher
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

3.  Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice.

Authors:  Peter J Gough; Ivan G Gomez; Paul T Wille; Elaine W Raines
Journal:  J Clin Invest       Date:  2005-12-22       Impact factor: 14.808

4.  Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation.

Authors:  Robert H Scannevin; Richard Alexander; Tara Mezzasalma Haarlander; Sharon L Burke; Monica Singer; Cuifen Huo; Yue-Mei Zhang; Diane Maguire; John Spurlino; Ingrid Deckman; Karen I Carroll; Frank Lewandowski; Eric Devine; Keli Dzordzorme; Brett Tounge; Cindy Milligan; Shariff Bayoumy; Robyn Williams; Celine Schalk-Hihi; Kristi Leonard; Paul Jackson; Matthew Todd; Lawrence C Kuo; Kenneth J Rhodes
Journal:  J Biol Chem       Date:  2017-08-31       Impact factor: 5.157

5.  Cathepsin G activity lowers plasma LDL and reduces atherosclerosis.

Authors:  Jing Wang; Sara Sjöberg; Ting-Ting Tang; Katariina Oörni; Wenxue Wu; Conglin Liu; Blandine Secco; Viviane Tia; Galina K Sukhova; Cleverson Fernandes; Adam Lesner; Petri T Kovanen; Peter Libby; Xiang Cheng; Guo-Ping Shi
Journal:  Biochim Biophys Acta       Date:  2014-08-01

6.  Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.

Authors:  Nicholas A Dewyer; Vikram Sood; Erin M Lynch; Catherine E Luke; Gilbert R Upchurch; Thomas W Wakefield; Steven Kunkel; Peter K Henke
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

7.  Expression of matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) induced by tumour necrosis factor alpha correlates with metastatic ability in a human osteosarcoma cell line.

Authors:  A Kawashima; I Nakanishi; H Tsuchiya; A Roessner; K Obata; Y Okada
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  A macrophage cell model for selective metalloproteinase inhibitor design.

Authors:  Faith E Jacobsen; Matthew W Buczynski; Edward A Dennis; Seth M Cohen
Journal:  Chembiochem       Date:  2008-09-01       Impact factor: 3.164

9.  Focal adhesion kinase functions as an akt downstream target in migration of colorectal cancer cells.

Authors:  Jolana Turecková; Martina Vojtechová; Michaela Krausová; Eva Sloncová; Vladimír Korínek
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

10.  Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway.

Authors:  Veronica C Ardi; Philippe E Van den Steen; Ghislain Opdenakker; Bernhard Schweighofer; Elena I Deryugina; James P Quigley
Journal:  J Biol Chem       Date:  2009-07-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.